Find policies, billing codes, payers, states, and providers
CPT 87635: Molecular Detection of SARS-CoV-2 by Amplified Probe Technique
CPT code 87635 represents a molecular diagnostic assay that uses an amplified nucleic acid probe technique to identify SARS‑CoV‑2, the virus responsible for COVID‑19. This code captures laboratory services for detection of viral nucleic acids and is a critical tool in clinical diagnosis, infection control, and public health surveillance. Nationally, SARS‑CoV‑2 testing remains central to pandemic response, clinical management, and screening strategies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and the payer landscape relevant to coverage and coding alignment. The publication also outlines related billing considerations and crosswalks to alternative SARS‑CoV‑2 test codes where applicable.
This analysis provides benchmarks for utilization and reimbursement patterns, highlights policy updates that affect laboratory reporting and billing, and situates CPT code 87635 within the broader clinical context of COVID‑19 testing. Intended for health system coders, laboratory managers, and policy analysts, the content focuses on accurate code identification, clinical application, and payer relevance at the national level.
Customize your policy alerts
Sign up for cpt 87635 policy alerts
Get alerted when payer policies referencing 87635 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 87635 describes a laboratory test that uses an amplified nucleic acid probe technique to detect nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) virus, the pathogen that causes coronavirus disease 2019 (COVID‑19).
Service type: Molecular diagnostic test for SARS‑CoV‑2 (COVID‑19)
Typical site of service: Clinical laboratory or hospital laboratory setting, performed by trained laboratory personnel using amplified nucleic acid technologies.
National Reimbursement Benchmarks
BUCA’s average commercial rate of $57.9 for CPT 87635 sits near the center of the market, offering a useful baseline against which individual payer distributions diverge. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $17.5, UnitedHealth Group’s spread is $20.5, and Aetna’s spread is $20.0; Cigna’s spread is the widest at $34.3. These differences indicate varying contract tightness around their medians and suggest more predictable payment bands for Blue Cross Blue Shield compared with Cigna.
In level terms, Aetna and Blue Cross Blue Shield have higher median or mean touchpoints than UnitedHealth Group and Cigna, while BUCA’s mean remains squarely mid-market. Cigna’s large P75–P25 gap of $34.3 reflects the greatest dispersion among the listed commercial payers, whereas Blue Cross Blue Shield’s $17.5 interquartile range is the tightest, implying more concentrated commercial rates for CPT 87635.